anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to urology. While performing transurethral ureteronephrolithotripsy and /or extraction, when the end of endoscope is at the ureteral meatus, supply of rinsing liquid is turned off. The water supply tube is disconnected from endoscope. A syringe filled with drotaverine hydrochloride is connected to liquid supply tap on the endoscope and depending on localization of stone in the ureter, the total volume of drotaverine hydrochloride is changed. With a stone of lower, middle and upper thirds of the ureter the total volume of medicine is 4-5-6 ml / 80-100-120 mg, respectively. Moreover, when an endoscope is installed at ureteral meatus, regardless of stone localization, 2 ml / 40 mg of drotaverine hydrochloride is injected, then after 3-4 minutes the endoscope is carried out behind the meatus into prevesical part of ureter and the remaining part is injected, and if: the stone is localized in the lower third of the ureter, then the volume of drotaverine hydrochloride injection will be 2 ml / 40 mg, the stone is localized in middle third of the ureter - 3 ml / 60 mg, the stone localized in the upper third of the ureter - 4 ml / 80 mg. Then, 3-4 minutes after injection, the syringe with the solution is changed to rinsing liquid supply tube and it is started at half flow and, in presence of already reduced ureter tone, an endoscope is brought to the stone and contact ureteronephrolithotripsy and / or extraction of the stone as a whole is performed.EFFECT: method allows simultaneously performing transurethral ureteronephrolithoextraction and contact ureteronephrolithotripsy using standard-sized endoscopes with a functionally narrowed lumen of the ureter and its meatus, in any hospital with equipment for endourological operations, to provide adequate urological care to patients with ureteral stones with its functionally narrowed lumen.1 cl, 3 ex
Striae distensae or stretch marks are a common complaint among women and can be distressing. The present study aimed to assess the efficacy of a mixture of low molecular weight hyaluronic acid and six amino acids when applied with a specific intradermal injection technique known as intra-mural fluid technique. A clinical study was carried out in 32 patients (with a dropout rate by 9.4%) with striae distensae alba (SA) in one or more of the following anatomical areas: breast, abdomen, inner thigh, trochanteric area, gluteal area, posterior supra-iliac area, and lumbar area. Product efficacy was assessed by the investigator using the Global Aesthetic Improvement Scale, while a Likert scale was used to evaluate to score the treatment tolerability and a QoL stretch marks questionnaire was used to investigate the patients' self-body image. The treatment was effective in improving the appearance of SA fifteen days after the second treatment and 6 months after the first treatment (and after a total of 4 treatments). The product efficacy and tolerability were also perceived by the patients during each treatment session. Our results suggest that the test treatment is a valid treatment option to decrease the appearance of SA. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors https://www.springer.com/00266.
BACKGROUND/AIM: Extreme hyperbilirubinemia is occasionally observed in intensive care unit (ICU) and non-ICU settings. This study examined the etiologies of extreme hyperbilirubinemia (bilirubin level ≥12 mg/dL) and the factors associated with the 30-day mortality.
METHODS: This retrospective observational cohort study identified 439 patients with extreme hyperbilirubinemia at the Gyeongsang National University Changwon Hospital between 2016 and 2020. The patients were classified into three groups and 11 diseases according to their etiology. The risk factors associated with 30-day mortality at the baseline were investigated using the Cox proportional hazards model.
RESULTS: Of 439 patients with extreme hyperbilirubinemia, 287, 78, and 74 were in the liver cirrhosis/malignancy group, the ischemic injury group, and the benign hepatobiliary-pancreatic etiological group, respectively, with corresponding 30-day mortality rates of 42.9%, 76.9%, and 17.6%. The most common disease leading to hyperbilirubinemia was a pancreatobiliary malignancy (28.7%), followed by liver cirrhosis (17.3%), hepatocellular carcinoma (10.9%), and liver metastases (8.4%). The etiologies of hyperbilirubinemia, obstructive jaundice, infection, albumin level, creatinine level, and prothrombin time-international normalized ratio were independently associated with the 30-day mortality.
CONCLUSIONS: This study suggests three etiologies of extreme hyperbilirubinemia in the ICU and non-ICU settings. The prognosis of patients with extreme hyperbilirubinemia depends largely on the etiology and the presence of obstructive jaundice.
Anxiety disorders are among the most common disorders in children. Although anxiety is a normal part of growing up, the worrying experienced by children with anxiety disorders can persist to the point that day-to-day functioning becomes difficult. Physical symptoms of anxiety disorders include a constant sense of worry or stress, headache, nausea, sweating, shaking, and inability to concentrate. Early identification of anxiety disorders is important to prevent progression of the disorder into a chronic issue. Cognitive behavioral therapy (CBT), which focuses on behavioral and thinking modifications, has been shown to be the most effective treatment for anxiety disorders. This study will evaluate the effectiveness of school-based CBT with or without parental involvement in treating anxious children who meet DSM-IV criteria or have features of separation anxiety disorder, generalized anxiety disorder, and social phobia.

Participants in this single blind study will be randomly assigned by school to one of three treatment groups: CBT for children only, CBT for children plus parent training, and no-treatment control. Each child and parent participant will first undergo an interview, lasting between 1 and 1.5 hours, about the child's symptoms. Additionally, parents will complete rating scales about their children's symptoms and their own symptoms. The participants receiving CBT will then attend 9 weekly group sessions held in the school buildings after school. In the parental involvement group, parents will attend 9 weekly group parent-training sessions held at the same time as the children's CBT group sessions. During the children's CBT sessions, participants will learn techniques to identify feelings of worry, relax, modify negative thoughts, break down difficult situations into smaller achievable steps, reward themselves for trying hard, and maintain treatment gains. For the parent training group, early sessions will focus on normalizing anxiety during childhood, learning about anxiety, and identifying when their children are feeling anxious. The middle sessions will teach parents the same anxiety management skills being taught to their children and ways to help their children to apply the steps at home. The latter sessions will instruct parents on ways to encourage their children's behaviors in anxiety-provoking situations. After completing the 9-week program, participants will attend 2 follow-up booster sessions at Months 1 and 3 post-treatment. Follow-up assessments will occur at Months 3 and 6 and at Years 1, 2, 3, and 4 post-treatment. The assessments will include repeat interviews and rating scales. At the end of the 6-month follow-up assessment, participants in the no-treatment control group will have the opportunity to participate in the CBT group treatments.
Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
Participants allocated to the Control group will receive usual care (i.e., no treatment for anxiety) and a mid-point check-in phone call/video call/email (depending on their preference) from the study team approximately 3 weeks after completing the initial questionnaires. This mid-point check-in is to identify whether there have been any changes to their usual care.
This retrospective study aimed to determine the incidence and risk factors for osteomyelitis recurrence and present our experiences in treating traumatic osteomyelitis in the lower leg and foot. We retrospectively reviewed data from 174 patients with distally based sural flaps for treating traumatic osteomyelitis with soft tissue defects in the lower leg and foot from November 2003 to February 2021. Possible risk factors for osteomyelitis recurrence were compared between the osteomyelitis control and recurrence groups. A total of 162 (93.1%) flaps survived uneventfully, while 12 (6.9%) flaps developed partial necrosis. Five patients had a bone defect with an average length of 5 cm. The free vascularized bone grafts were performed in two patients, and bone transportations were performed in three patients. All patients were followed up with an average period of 72.8 months. There were 152 patients (87.4%) in control group and 22 patients (12.6%) in recurrence group. The recurrence rates of osteomyelitis were significantly higher when the patient's age was 40 years or more and the duration was 10 weeks or more (P < 0.05). Cierny-Mader (C-M) classification type IV osteomyelitis was also significantly associated with osteomyelitis recurrence (p = 0.049). This flap combined with appropriate osteomyelitis treatment was an effective method to treat traumatic osteomyelitis of lower leg and foot with a soft tissue defect. Both patient age ≥ 40 years old and C-M type IV osteomyelitis were nonnegligible risk factors for osteomyelitis recurrence.
The study hypothesis is to proceed and to undergo an intensively long-term clinical management and laboratory examinations for asymptomatic infants with MPS I in order to be able to give an enzyme replacement therapy (ERT) in a timely fashion. The overall objectives of this study are summarized as follows, including: 1. To plan a three-month or six-month interval of recall process depending on the judgment of individual case by pediatric geneticist. 2. To recall the asymptomatic MPS I infants back to MacKay Memorial Hospital for MPS follow-up examinations, including regular physical examinations for the earliest presenting symptoms such as otitis media, abdominal or inguinal hernia, and coarse facial features, as well as the urinary biochemistry glycosaminoglycan (GAG) tests. 3. To give ERT in time whenever the typical MPS signs or symptoms showed up. 4. To achieve the aim of newborn screening for MPS, "Early detection, making early diagnosis, and providing early therapy can effectively prevent the development of severe clinical manifestations".
For best viewing and patient comfort, the Lissamine Green impregnated tip should be moistened with one or two drops of sterile irrigating or saline solution before application. Apply moistened tip to conjunctiva or fornix as required. It is recommended that the patient blink several times after application. 

1\. Hold package in middle and tear down toward sterile strip

2\. Turn over and tear down from other side, taking care not to tear the sterile strip.

3\. Grasp each end of package firmly as shown, without touching the sterile strip, and pull apart.
Methods for the top-down design of nucleic acid nanostructures of arbitrary geometry based on target shape of spherical or non-spherical topology are described. The methods facilitate 3D molecular programming of lipids, proteins, sugars, and RNAs based on a DNA scaffold of arbitrary 2D or 3D shape. Geometric objects are rendered as node-edge networks of parallel nucleic acid duplexes, and a nucleic acid scaffold routed throughout the network using a spanning tree formula. Nucleic acid nanostructures produced according to top-down design methods are also described. In some embodiments, the nanostructures include single-stranded nucleic acid scaffold, DX crossovers, and staple strands. In other embodiments, the nanostructures include single-stranded nucleic acid scaffold, PX crossovers and no staples. Modified nanostructures include chemically modified nucleotides and conjugated to other molecules are described.
OBJECTIVE: To evaluate the rates of exclusive breastfeeding (EBF) and growth of preterm and/or low birth weight newborns during the third stage of the Kangaroo Method (TSKM), at discharge.
METHODS: Retrospective study in a reference public maternity hospital between Jan/2014 and Dec/2017, including the preterm (less than 37 weeks) and/or low birth weight (less than 2500 g) newborn infants. Information was collected from medical records. Statistics analysis was done in SPSS software.
RESULTS: 482 infants were included and followed up at the TSKM ambulatory. The average gestational age was 33 weeks (variation: 24-39 weeks) and birth weight, 1715g (variation: 455-2830 g). EBF occurred in 336 (70.1%) infants at hospital discharge, and in 291 (60.4%) at TSKM discharge. Each additional day of hospital stay increased the chance of infant formula (IF) use by 9.3% at hospital discharge and by 10.3% at TSKM discharge. Staying in the Kangaroo Neonatal Intermediate Care Unit (KNICU) favored EBF at hospital discharge and TSKM discharge (p<0.001). Not performing the kangaroo position increased the chance formula administration to the newborn infant at hospital discharge by 11%. Weight gain and head circumference growth were higher in infants using formula (p<0.001).
CONCLUSIONS: The length of hospital stay and not performing the kangaroo position favored the use of infant formula at hospital and TSKM discharge. Staying in the KNICU favored exclusive breastfeeding at hospital and TSKM discharge. Weight gain and HC growth were higher in newborns receiving infant formula.
UNLABELLED: The relationship between follicle size, oocyte quality, and blastocyst ploidy is not fully established. This question becomes especially important for poor responders and older reproductive age women, where optimal follicle size and oocyte quantity cannot always be achieved during ovarian stimulation. The aim of this study is to determine the relationship between follicle size, oocyte maturation, blastocyst formation, blastocyst ploidy, and pregnancy outcomes in young women undergoing in vitro fertilization (IVF).
MATERIALS AND METHODS: The study involved 32 oocyte donors aged 19 to 35. For ovarian stimulation, a protocol with GnRH-antagonists was used, employing downregulation with oral contraceptives. The ovulation trigger was administered when 20% of follicles reached 18 mm. Aspiration was performed 35 hours after the ovulation trigger was administered. Follicle size was measured immediately before the aspiration needle was inserted and follicle fluid was aspirated; data (follicle size and oocyte from this follicle) were recorded individually by the embryologist. The resulting blastocysts underwent preimplantation genetic testing for aneuploidy (PGT-A) using NGS. Pregnancy outcomes were assessed by biochemical indicators, miscarriages, and live births.
RESULTS: Out of 555 measured follicles, 508 oocytes were obtained (91.5%). The number of mature oocytes (MII) was 411 (80.9%), and there were 97 immature oocytes (19.2%). Out of the 97 immature oocytes, 51 were germinal vesicle (GV) oocytes (10.04%), and 46 (9.06%) were MI oocytes without a polar body. Follicles were divided into four groups based on size: Group I - <15 mm, Group II - 15-18 mm, Group III - 18-20 mm, Group IV - >20 mm. There were significantly more mature oocytes in the second, third, and fourth groups compared to the first, indicating that follicle size has a substantial impact on retrieving MII oocytes (p<0.0001). Especially high number of mature oocytes were observed in the second and third groups. Fertilization and blastocyst formation from oocytes obtained from larger follicles were higher than from smaller follicles (p<0.0001). The frequency of obtaining euploid blastocysts did not significantly differ between the groups, and no significant relationship was found between follicle size and the formation of euploid blastocysts. Women who underwent genetic testing of embryos and transferred euploid embryos had significantly lower rates of biochemical pregnancy and miscarriages, as well as significantly higher live birth rates compared to those who did not undergo genetic testing of embryos.
CONCLUSION: Oocyte maturation, fertilization, and blastocyst formation depend on follicle size. However, follicle size is not an indicator of blastocyst euploidy. Preimplantation genetic testing for aneuploidy (PGT-A) significantly increases pregnancy success and live birth rates while reducing miscarriage rates.
NEW MATERIAL:Pfaffic acid and its derivative of the formula (R1 is H or acyl; R2 is H or alkyl). USE:An antitumor agent, capable of exhibiting improved inhibitory activity against melanoma cells, cervical cancer cells, cancer cells of the lung, etc. in a concentration as low as 4-6mug/ml, and administered in 10mg-1g, preferably about 100mg daily dose in the form of a powder, granule, capsule, solution, etc. PROCESS:The root of a dried Pfaffia paniculate Kuntze is pulverized and extracted with an alcohol, and sulfuric acid is then added to the resultant extract solution and refluxed under heating to distill away the solvent. The residue obtained by the distillation is then passed through a column packed with silica gel, and eluted with a mixture of chloroform with methanol at (50:1)-(20:1) ratio. The solvent is then distilled from the eluted fraction to recrystallize the residue from the alcohol and give the aimed pfaffic acid of the formula. The pfaffic acid of the formula is a crystalline substance having specific <=29C skeleton, and stable to acids and alkalis with 285-286 deg.C melting point.
Insert needle with aseptic precautions. With tip free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. Then inject VITRASE into rubber tubing close to needle.

An alternate method is to inject VITRASE under skin prior to clysis. 200 Units will facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer’s, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration.

VITRASE may be added to small volumes of solution (up to 200 mL), such as small clysis for infants or solutions of drugs for subcutaneous injection. For infants and children less than 3 years old, the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older patients, the rate and volume of administration should not exceed those employed for intravenous infusion.
The present invention relates to the therapeutic use of molecules which bind and neutralize IFN-.gamma. in primates. More specifically, the present invention relates to the use of an anti-primate IFN-.gamma. antibody for preventing or treating diseases wherein IFN-.gamma. is pathogenic. The prese nt invention further relates to a pharmaceutical composition comprising the ant i- primate IFN-.gamma. antibody D9D10 for preventing or treating pathological reactions caused by IFN-.gamma..
BACKGROUND: Life expectancy of children with chronic intestinal failure (CIF) on home parenteral nutrition has greatly improved. Children are now able to grow into adulthood which requires transfer from pediatric to adult health care. A guideline for structured transition is lacking and the demand for a more standardized care for this patient group is necessary. Therefore, we investigated the perceptions of health care professionals from various disciplines working in this specific field, concerning effective interventions regarding transition to adult health care.
AIM: To create a standardized protocol which provides practical guidance for health care professionals in order to bridge the gap between pediatric and adult health care and to facilitate successful transition of children with chronic intestinal failure.
METHODS: A survey consisting of 20 interventions for transition was sent out to members of the Intestinal Failure working group of European Reference Network for Rare Inherited Congenital (gastrointestinal and digestive) Anomalies (ERNICA) and the Network of Intestinal Failure and Intestinal Transplant in Europe (NITE) group - European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) healthcare professionals in 48 medical centers in various countries. Next to 20 interventions, an open-ended question to fill in any other suggestion with respect to most effective intervention was included. Interventions scoring higher than 80% by the participants were included in the protocol. Interventions scoring between 50% and 80% and other own suggestions were discussed during a consensus meeting and included when consensus, defined as unanimous agreement, was reached. Interventions scoring as effective by < 50% of participants were excluded directly.
RESULTS: A total of 80 healthcare professionals from 33 medical centers (participation rate 69%) participated. The protocol consisted of modifiable components expected to be targets of interventions. The most important key outcomes of the survey were: 1) assessment of patient's transition readiness and provision of knowledge to the patient by the pediatric team, 2) involvement of parents in the transition process, and 3) collaboration between the pediatric and adult chronic intestinal failure team. In addition it is advised that the transition process should start 1-2 years before transfer. A nurse specialist working in both services should form a bridge. All interventions must be tailor-made and based on the maturity of the patient.
CONCLUSION: This study provides a protocol describing transition of children with chronic intestinal failure from pediatric to adult care. This international protocol will serve as practical guidance for pediatric chronic intestinal failure which will provide a more structured, optimal transition process. It is advised to use this protocol as a formal checklist that can be placed in the patient's chart to review and track the transition process by CIF team members. Future research investigating transition readiness of CIF patients is needed.
Isolated nucleic acids encoding allergens of  Canis familiaris , Canf I or Can f II. are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.